Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial

NCT05162482 is registered in ClinicalTrials.gov with Aga Khan University Hospital, Pakistan as lead sponsor.

NCT NCT05162482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial
Lead sponsor
Aga Khan University Hospital, Pakistan
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2022
Completion date
June 30, 2024
Enrollment
1,680 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19 vaccine